BBarclays MMarvell · MRVL

Barclays Reiterates Equalweight Rating on Marvell (March 6)

Mar 6, 2026· 1 min read· Reproduced verbatim
Rating
Unknown
Price target
$105
Previous
Implied upside
+39%

Barclays analyst Tom O’Malley reiterated an Equalweight rating and $105.00 price target on Marvell Technology (NASDAQ: MRVL).

“The solid print the company needed after laying out the multi-year guide last quarter.

Optical is the major change, now >50% Y/Y (vs. prior 30%) and FY28 is tracking better than prior cloud capex guide.

Custom ASIC guidance implies ~$3.8B revenue in FY28 on our ests., including ~$1B of XPU attach, which leaves ~$2.8B between AMZN and MSFT.

Our view is that the guide bakes in some MSFT today (>$600M) with the rest coming from AMZN and there is nearly 3x upside to MSFT if orders come through.

Even assuming share loss at AMZN and little MSFT, the company is tracking towards $5 in EPS making the name cheap at these levels. AEC and retimer revenue at ~$200M and could “keep doubling” from here.

Execution has been a sticking point but if the company keeps lining up beats, we see a path to a strong stock move higher.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.